Allfunds Group plc (FRA:6UY)

CTI BioPharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	-	2,628	2,101	1,623	2,193	1,849
Short-Term Investments	-	103.32	154.15	161.61	61.72	0.39
Trading Asset Securities	-	12.14	14.13	0.34	0.38	0.51
Cash & Short-Term Investments	-	2,744	2,269	1,785	2,255	1,850
Cash Growth	-	20.90%	27.11%	-20.82%	21.89%	76.95%
Accounts Receivable	-	249.86	239.59	903.76	883.09	605.53
Other Receivables	-	5.53	3.33	33.42	37.9	64.91
Receivables	-	255.38	242.92	937.17	920.99	670.44
Prepaid Expenses	-	3.4	2.87	1.44	2.88	1.29
Other Current Assets	-	3.63	3.49	6.79	9.91	5.56
Total Current Assets	-	3,006	2,519	2,731	3,188	2,527
Property, Plant & Equipment	-	23.76	31.28	25.84	28.05	29.3
Goodwill	-	1,040	1,276	1,129	1,008	1,002
Other Intangible Assets	-	956.42	1,089	1,131	1,195	1,329
Long-Term Accounts Receivable	-	2.29	1.26	0.8	0.96	0.87
Long-Term Deferred Tax Assets	-	43.31	92.75	110.17	125.42	55.11
Total Assets	-	5,072	5,010	5,127	5,546	4,943
Accounts Payable	-	17.16	10.18	12.57	24.11	18.72
Accrued Expenses	-	30.8	26.45	14.41	30.11	22.35
Current Portion of Leases	-	6.42	7.04	5.69	7.12	7.29
Current Income Taxes Payable	-	27.66	26.03	29.11	52.1	15.15
Current Unearned Revenue	-	-	0.74	522.1	601.71	352.16
Other Current Liabilities	-	2,381	1,988	1,779	2,221	1,813
Total Current Liabilities	-	2,463	2,059	2,362	2,937	2,229
Long-Term Debt	-	392	366.95	193.98	47.25	-
Long-Term Leases	-	11.65	16.51	11.16	12.73	12.19
Long-Term Deferred Tax Liabilities	-	148.33	188.56	204.15	223.22	327.39
Other Long-Term Liabilities	-	7.01	24.29	0.2	0.2	-
Total Liabilities	-	3,027	2,659	2,773	3,222	2,568
Common Stock	-	1.53	1.55	1.57	1.57	1.57
Additional Paid-In Capital	-	1,960	2,010	2,060	2,060	2,060
Retained Earnings	-	66.1	292.52	263.35	246.14	313.01
Treasury Stock	-	-6.02	-8.86	-10	-	-
Comprehensive Income & Other	-	23.39	55.52	39.43	16.46	0.53
Shareholders' Equity	-	2,045	2,351	2,355	2,324	2,375
Total Liabilities & Equity	-	5,072	5,010	5,127	5,546	4,943
Total Debt	-	410.07	390.49	210.82	67.09	19.48
Net Cash (Debt)	-	2,333	1,879	1,574	2,188	1,830
Net Cash Growth	-	24.20%	19.33%	-28.03%	19.52%	78.19%
Net Cash Per Share	-	3.83	3.04	2.54	3.48	11.63
Filing Date Shares Outstanding	-	609.79	618.83	628.05	629.43	157.36
Total Common Shares Outstanding	-	609.79	618.83	628.05	629.43	157.36
Working Capital	-	542.86	459.64	368.28	251.87	298.57
Book Value Per Share	-	3.35	3.80	3.75	3.69	15.09
Tangible Book Value	-	48.4	-14.82	94.89	121.2	44.27
Tangible Book Value Per Share	-	0.08	-0.02	0.15	0.19	0.28
Machinery	-	17.72	18.18	16.78	16.18	15.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.